Bli medlem
Bli medlem

Du är här

2016-11-02

Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health

Enzymatica has partnered with Endeavour Consumer Health, a division of Symbion
which is a member of EBOS Group. The agreement grants Endeavour Consumer
Health exclusive rights to sell, market and distribute ColdZyme® in Australia
and New Zealand. It is Enzymatica's first agreement outside the European
Union (EU) and a breakthrough in the company's strategic initiative to
further establish ColdZyme in the international market.

The agreement covers the products ColdZyme 20ml and ColdZyme OneCold 7ml.

The regulatory requirements for medical devices in Australia differ from those
in the EU, meaning ColdZyme will be registered in a higher class of medical
devices. The registration process is expected to take 12-18 months and the
launch is planned for 2018, ready for the cold&flu season in Australia.

"The agreement with Endeavour Consumer Health is an important breakthrough in
our strategic international expansion outside Europe, and Endeavour Consumer
Health is the perfect partner for us. They are well established and have
significant experience launching new products to the market, which will
favour the introduction of ColdZyme in Australia and New Zealand", said
Fredrik Lindberg, CEO of Enzymatica.
EBOS Group's General Manager - Retail Services, Andrew Vidler, said ColdZyme
would complement Endeavour Consumer Health's existing product offering.

"We are very excited about the agreement with Enzymatica to sell ColdZyme in
Australia. ColdZyme is different to traditional cold therapies and fits well
into our business model to grow our business in the over the counter (OTC)
health products market with innovative new products."

For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB

Tel: +46 708-86 53 70 | E-post:fredrik.lindberg@enzymatica.com

This information is information that Enzymatica AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person set out
above, at 16.00 CET on November 2, 2016.

About Enzymatica

Enzymatica AB is a Life sciences company that develops and sells medical
devices for fighting infectious diseases. In a short period of time, the
company developed ColdZyme®, a unique mouth spray for fighting colds,
launched the product in seven markets and established it as one of the
bestselling cold products in Swedish pharmacies measured in SEK. Our strategy
is to continue growing by strengthening our position on existing markets and
expanding to more geographic markets via established partners. The company's
head office is in Lund and it is listed on the Nasdaq First North. For more
information, please go to:www.enzymatica.se.

Enzymaticas Certified Adviser is Erik Penser Bankaktiebolag.

About Endeavour Consumer Health

Endeavour Consumer Health is a trans-Tasman business dedicated to providing
its retail partners and their customers with affordable, high-quality health
and personal care products.

The business was formed in 2014 from the amalgamation of Symbion Consumer
Products in Australia and the consumer division of EBOS Healthcare in New
Zealand and Australia.

Endeavour Consumer Health is part of Symbion, a member of EBOS Group Ltd.
EBOS Group is the largest and most diversified Australasian marketer,
wholesaler and distributor of healthcare, medical and pharmaceutical
products.

For more information visitwww.ebosgroup.com

Enzymatica Press Release Australia 161102 Final version
http://hugin.info/160850/R/2053698/768657.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.